Skip to content

A clinical trial to see effect of IP in alcohol hangover.

A prospective randomized double blinded pilot study to evaluate the efficacy of IP to treat hangover post alcohol consumption.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025404
Enrollment
20
Registered
2020-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Venerg-UTM: Each tablet contains multiple plant extracts. Control Intervention1: Placebo: The placebo product contains 4 g of Nutraceuticals grade excipients tablet.

Sponsors

Synthite Industries Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy Male or Female aged 21-40 years 2. Subjects are able and agrees to drink alcohol 3. Subjects willing to comply to study procedure and sign written informed consent 4. Healthy subjects, who self-reports not to have any history of concomitant medication or illness and the subjects, who are not on any medication. 5. Psychologically stable subjects 6. Subjects having normal sleep patterns.

Exclusion criteria

Exclusion criteria: 1. Subjects, who have had experienced illness apart from hangover after alcohol consumption. 2. Subjects on any kind of medications 3. Subjects undergoing treatment for any condition 4. History of chronic smoking, alcoholism, psychiatric disorders, drug abuse or dependence, or regular use of psychoactive drugs 5. Breast feeding women 6. Pregnant women 7. Subject planning to conceive. 8. Subjects participating in another clinical trial or subjects participated in any clinical trial within last 6 months. 9. Any condition that in the opinion of the investigator does not justify the subjectâ??s inclusion for the study. 10. Subjects who have consumed alcohol within past 24 hours. 11. Subjects donâ??t have any chronic liver and kidneys disease.

Design outcomes

Primary

MeasureTime frame
1. To check, if the unit dose of 1 tablet (4g) in 250 ml water is sufficient to treat the hangover. 2. To check effect of IP on Serum Alcohol (Ethanol) concentration at baseline and EOT 3. To check the consumption time of the IP Summary of change: The pre-established Aldehyde dehydrogenase test has been replaced with Serum alcohol(ethanol) test as per the direction of the Sponsor. Timepoint: 1 Day

Secondary

MeasureTime frame
Understanding the hangover effect and associated symptom/disordersTimepoint: 1 Day

Countries

India

Contacts

Public ContactSubham Dutta

Synthite Industries Pvt Ltd

neeleshk@synthite.com7356480222

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026